Results 51 to 60 of about 28,326 (256)

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

FEBS Open Bio, EarlyView.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo, Keisuke Okuno, Shuichi Watanabe, Sakiko Oba, Hiroyasu Kagawa, Masanori Tokunaga, Daisuke Ban, Yusuke Kinugasa   +7 more
wiley   +1 more source

New Frontiers in Diagnosis and Therapy of Circulating Tumor Markers in Cerebrospinal Fluid In Vitro and In Vivo

Cells, 2019
One of the greatest challenges in neuro-oncology is diagnosis and therapy (theranostics) of leptomeningeal metastasis (LM), brain metastasis (BM) and brain tumors (BT), which are associated with poor prognosis in patients.
Olga A. Sindeeva, Roman A. Verkhovskii, Mustafa Sarimollaoglu, Galina A. Afanaseva, Alexander S. Fedonnikov, Evgeny Yu. Osintsev, Elena N. Kurochkina, Dmitry A. Gorin, Sergey M. Deyev, Vladimir P. Zharov, Ekaterina I. Galanzha   +10 more
doaj   +1 more source

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop. [PDF]

The implementation of circulating tumor DNA (ctDNA) in the diagnostic routine may enable non-invasive predictive biomarker testing and treatment optimization in patients who lack a suitable tumor specimen, have failed previous molecular analysis or are ...
Patton, SJ, Koch, C, Schuuring, E, Heitzer, E, Giacomini, P, Fairley, JA, Joosse, SA, ELBS ctDNA Workshop Group, Toledo, RA, Deans, ZC, Pantel, K, de Jager, VD   +11 more
core   +1 more source

A Dual‐Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy

Advanced Science, EarlyView.
ABSTRACT Liquid biopsy technology, which detects circulating tumor DNA (ctDNA) in cerebrospinal fluid, plays a crucial role in the early diagnosis and precision treatment of gliomas. However, the intrinsically low abundance and rapid clearance of ctDNA pose substantial challenges for conventional analytical techniques, such as droplet digital PCR and ...
Yu Sun, Jing Zhang, Chenqing Liu, Jing Lou, Sihui Wang, Xiangtian Ji, Xiaofang Zhao, Shirui Xu, Jingyu Feng, Bin Liu, Chao Chang, Qinggang Ge, Jun Yang   +12 more
wiley   +1 more source

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC

Molecular Oncology, 2023
Brain metastasis (BM) genetically diverges from the primary tumor in non‐small‐cell lung cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the delivery of targeted therapies.
Jun Wu, Zhiqiang Liu, Tianxiang Huang, Ying Wang, Meng Meng Song, Tao Song, Gretchen Long, Xiaobing Zhang, Xi Li, Longbo Zhang   +9 more
doaj   +1 more source

State of the Art: ctDNA in Upper Gastrointestinal Malignancies

, 2023
Circulating tumor DNA (ctDNA) has emerged as a promising non-invasive source to characterize genetic alterations related to the tumor. Upper gastrointestinal cancers, including gastroesophageal adenocarcinoma (GEC), biliary tract cancer (BTC) and ...
Ibone Labiano, Maria Alsina, Ana Elsa Huerta, Irene Hernandez-Garcia, Elena Mata, Hugo Arasanz, Ruth Vera, Virginia Arrazubi, David Gomez   +8 more
core   +1 more source

Advances in Gastric Cancer Research: Insights Into Carcinogenesis, the Tumor Microenvironment, Metastasis, and Factors Influencing Prognosis

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Department of Gastroenterological Surgery at Kumamoto University has maintained a commitment to integrating cutting‐edge clinical practice with fundamental research, particularly concerning malignant diseases of the digestive tract.
Hideo Baba, Takatsugu Ishimoto, Yoshifumi Baba, Hiromitsu Hayashi, Masaaki Iwatsuki   +4 more
wiley   +1 more source

Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients

Cancer Research, Statistics, and Treatment, 2019
Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey, Sarjana Dutt, Anjana Singh, Amit Kumar, Shivkant Singh   +4 more
doaj   +1 more source

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma

Frontiers in Oncology, 2022
Majority of patients with resected early- and intermediate-stage liver cancer will experience postoperative recurrence. This study aimed to investigate the application of ctDNA sequencing in the postoperative period of hepatocellular carcinoma.
Ke Ye, Qinqiao Fan, Mingming Yuan, Dong Wang, Liang Xiao, Guo Long, Rongrong Chen, Tongdi Fang, Zengbo Li, Ledu Zhou   +9 more
doaj   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source